Noa G. Holtzman

Noa G. Holtzman

Auto-generated profile, based on publicly available information

Noa G. Holtzman

Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2020 in Neuro-Oncology
Verified
Journal Article
Closed access
NHNoa G Holtzman
Noa G Holtzman
HXHao Xie
Hao Xie
SBSoren Bentzen
Soren Bentzen
VKVivek Kesari
Vivek Kesari
ABAli Bukhari
Ali Bukhari
SDSaurabh Dahiya
Saurabh Dahiya
Background: CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associated neurotoxicity syndrome (ICANS), is poorly understood. To better elucidate the clinical characteristics, treatment outcomes, and correlative biomarkers of ICANS, we review here a single-center analysis of ICANS after CAR T-cell therapy in R/R LBCL.Methods: Patients (n = 45) with R/R LBCL treated with axicabtagene ciloleucel (axi-cel) were identified. Data regarding treatment course, clinical outcomes, and correlative studies were collected. Patients were monitored and graded for ICANS via CARTOX-10 scoring and Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria, respectively.Results: Twenty-five (56%) patients developed ICANS, 18 (72%) of whom had severe (CTCAE grades 3–4) ICANS. Median time to development of ICANS was 5 days (range, 3–11). Elevated pre-infusion (day 0 [D0]) fibrinogen (517 vs 403 mg/dL, upper limit of normal [ULN] 438 mg/dL, P = 0.01) and D0 lactate dehydrogenase (618 vs 506 units/L, ULN 618 units/L, P = 0.04) were associated with ICANS. A larger drop in fibrinogen was associated with ICANS (393 vs 200, P < 0.01). Development of ICANS of any grade had no effect on complete remission (CR), progression-free survival (PFS), or overall survival (OS). Duration and total dose of steroid treatment administered for ICANS did not influence CR, PFS, or OS.Conclusions: ICANS after CAR-T with axi-cel for R/R LBCL was seen in about half of patients, the majority of which were high grade. Contrary to previous reports, neither development of ICANS nor its treatment were associated with inferior CR, PFS, or OS. The novel finding of high D0 fibrinogen level can identify patients at higher risk for ICANS.

9 September 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
FLForat Lutfi
Forat Lutfi
NHNoa G. Holtzman
Noa G. Holtzman
AKAnkit J. Kansagra
Ankit J. Kansagra
MAMoaath Mustafa Ali
Moaath Mustafa Ali
ABAli Bukhari
Ali Bukhari
SDSaurabh Dahiya
Saurabh Dahiya

18 February 2021 in Blood
Verified
Journal Article
Open access
PDF file
LCLauren M. Curtis
Lauren M. Curtis
AOAlen Ostojić
Alen Ostojić
DVDavid J. Venzon
David J. Venzon
NHNoa G. Holtzman
Noa G. Holtzman
FPFilip Pirsl
Filip Pirsl
SPSteven Z. Pavletic
Steven Z. Pavletic
Steroid-refractory chronic graft-versus-host disease (cGVHD) is a therapeutic challenge. Sclerotic skin manifestations are especially difficult to treat. We conducted a randomized phase 2 clinical trial (#NCT01688466) to determine the safety, efficacy, and preferred dose of pomalidomide in persons with moderate to severe cGVHD unresponsive to corticosteroids and/or subsequent lines of therapy. Thirty-four subjects were randomized to receive pomalidomide 0.5 mg per day orally (n = 17; low-dose cohort) or 2 mg per day at a starting dose of 0.5 mg per day increasing to 2 mg per day over 6 weeks (n = 17; high-dose cohort). The primary endpoint was overall response rate (ORR) at 6 months according to the 2005 National Institutes of Health cGVHD Response Criteria. Thirty-two patients had severe sclerotic skin and received a median of 5 (range, 2-10) previous systemic therapies. ORR was 47% (95% confidence interval, 30-65) in the intention-to-treat analyses. All were partial responses, with no difference in ORR between the cohorts. ORR was 67% (45%-84%) in the 24 evaluable subjects at 6 months. Nine had improvement in National Institutes of Health joint/fascia scores (P = .018). Median change from the baseline in body surface area involvement of skin cGVHD was −7.5% (–10% to 35%; P = .002). The most frequent adverse events were lymphopenia, infection, and fatigue. Eight subjects in the high-dose cohort had dose decreases because of adverse events. There was 1 death in the low-dose cohort from bacterial pneumonia. Our data indicate antifibrotic effects of pomalidomide and possible association with increases in concentrations of blood regulatory T-cell and interleukin-2. Pomalidomide 0.5 mg per day is a safe and effective therapy for advanced corticosteroid-refractory cGVHD.

19 July 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
YPYifan Pang
Yifan Pang
ACAnanth V. Charya
Ananth V. Charya
MKMichael B. Keller
Michael B. Keller
ASArlene Sirajuddin
Arlene Sirajuddin
YFYi-Ping Fu
Yi-Ping Fu
SASean Agbor-Enoh
Sean Agbor-Enoh
Pulmonary chronic graft-versus-host disease (PcGVHD) is a devastating complication of allogeneic hematopoietic stem cell transplant (HCT). The 2014 National Institutes of Health cGVHD consensus criteria (NIH criteria) only captures bronchiolitis obliterans syndrome (BOS). In this study, we adapted the 2019 International Society for Heart and Lung Transplantation (ISHLT) criteria of chronic lung allograft dysfunction (CLAD) to define novel phenotypes of PcGVHD and compared the performance of this criteria with the NIH criteria to identify patients with high-risk PcGVHD. We reviewed consecutive patients in a cGVHD natural history protocol (#NCT00092235) and adapted the 2019 CLAD criteria (the adapted criteria) to define PcGVHD as post-HCT forced expiratory volume at 1 second < 80% predicted value, with 4 phenotypes: obstructive, restrictive, mixed obstructive/restrictive, and undefined. An independent adjudication committee evaluated subjects for diagnosis and phenotyping. We identified 166 (47.4%) patients who met the adapted criteria, including obstruction (n = 12, 3.4%), restriction (n = 67, 19.1%), mixed obstruction/restriction (n = 47, 13.4%), and undefined (n = 40, 11.4%). In these patients, less than half (n = 78) met the NIH criteria for BOS (NIH+); the rest (n = 88) did not (NIH−). The NIH− subjects showed increased risk of death compared with those without PcGVHD (hazard ratio = 1.88, 95% confidence interval = 1.20-2.95; P = .006) that was similar to NIH+ subjects (P = .678). Our study demonstrated the potential of the adapted criteria in identifying patients with high-risk PcGVHD that have been missed by the NIH criteria. The adapted criteria could become a valuable tool to better phenotype and study lung disease in cGVHD.

24 July 2025 in British Journal of Haematology
Verified
Journal Article
Open access
ADAlexandra Dreyzin
Alexandra Dreyzin
NHNoa G. Holtzman
Noa G. Holtzman
CBChallice L. Bonifant
Challice L. Bonifant
Summary: Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with variable anti‐tumour responses and toxicities observed. Here, we review the clinical outcomes of these therapies, including monoclonal antibodies and antibody‐drug conjugates, as well as bispecific T‐cell engager molecules and chimeric antigen receptor (CAR) T cells. We discuss the potential reasons for therapy‐associated toxicity and limited efficacy, including differential antigen expression, the AML microenvironment and patient‐derived T‐cell fitness. To address these challenges, we highlight novel approaches to CD123 targeting currently in preclinical development. Promising new strategies include combination therapies that target CD123 and other known AML‐associated antigens such as CD33 or CLL‐1, NK‐cell‐based cell therapies, and bispecific‐secreting T cells.

7 December 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
KJKhushali S. Jhaveri
Khushali S. Jhaveri
ISIlana Schlam
Ilana Schlam
NHNoa G. Holtzman
Noa G. Holtzman
MPMonica Peravali
Monica Peravali
PRPerry K. Richardson
Perry K. Richardson
ARAaron P. Rapoport
Aaron P. Rapoport
Key Points: CAR T-cell therapy was safe and effective in a DLBCL patient with coexisting autoimmune neuropathy. CD19 CAR T-cell therapy may control refractory autoantibodies and monoclonal gammopathies.